Compugen Ltd. · NASDAQ:CGEN

Compugen — Investor Presentation (November 2020)

36 slides from Compugen's investor presentation, November 2020

  1. Slide 1: Corporate Overview

    CORPORATE OVERVIEW November 2020

  2. Slide 2: Safe Harbor Statement

    SAFE HARBOR STATEMENT This presentation contains “forward-looking statements” within the meaning of the the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements c

  3. Slide 3: Our Vision: From Code to Cure

    OUR VISION ® FROM CODE TO CURE Transforming patient lives by developing first- in-class therapeutics based on Compugen’s computational target discovery platform www.cgen.com I 3

  4. Slide 4: Investment Highlights

    INVESTMENT HIGHLIGHTS Innovative Encouraging Preliminary Strategic Computational Immuno-Oncology Portfolio Clinical Data Collaborations Platform First-in-Class Drugs Well-Tolerated with Signals External Validation of From Code to Clinic of Anti-Tumor Activity Targets & Approach • Phase 1 drug candid

  5. Slide 5: Strong Execution and Near-Term Value Drivers

    STRONG EXECUTION AND NEAR-TERM VALUE DRIVERS COM701 COM902 • Presented encouraging data from monotherapy and combination • Initiated Phase 1 dose escalation study all comers with Opdivo® dose escalation studies at AACR in patients with advanced solid malignancies in • Completed enrollment in combina

  6. Slide 6: Leadership Team

    LEADERSHIP TEAM Management Team Board Of Directors Paul Sekhri Chairman of the Board Anat Cohen-Dayag, PhD Anat Cohen-Dayag, PhD Ari Krashin Henry Adewoye, MD President & CEO, Director President and CEO Chief Financial & Operating Officer SVP & Chief Medical Officer Jean-Pierre Bizzari, MD Director

  7. Slide 7: Strategic Advisors

    STRATEGIC ADVISORS Industry Veterans, Renowned Oncologists and Immunologists Scientific Advisory Board Drew Pardoll, MD, PhD Antoni Ribas, MD, PhD Nils Lonberg, PhD Elliott Sigal, MD, PhD Chairman Former SVP, Oncology Discovery Biology Strategic Advisor Multi-year strategic collaboration Bristol Mye

  8. Slide 8: Computational Discovery Platform

    COMPUTATIONAL DISCOVERY PLATFORM www.cgen.com I

  9. Slide 9: From Target Discovery to Clinical Validation

    FROM TARGET DISCOVERY TO CLINICAL VALIDATION Proven Computational Approach to Discover New Biological Pathways for I/O Drug Targets RNASeq Novel Targets PROPRIETARY COMPUTATIONAL TOOLS AND ALGORITHMS Single Cell RNA First-in-Class Drug Candidates Curation Annotation Integration Microarray Novel Biom

  10. Slide 10: Significant Unmet Need

    SIGNIFICANT UNMET NEED 70-80% of Patients Non-responsive to Approved Cancer Immunotherapies PD-1 monotherapy/combination activity across indications • New drug targets aimed to address 100 ~20-30% Average non-responsive patient populations Overall response Rate % 90 80 Response Rate 70 65 58 58 • Me

  11. Slide 11: Versatile Computational Discovery Platforms to Address Immune Resistance

    VERSATILE COMPUTATIONAL DISCOVERY PLATFORMS TO ADDRESS MULTIPLE MECHANISMS OF IMMUNE RESISTANCE INFLAMED EXCLUDED/SUPPRESSED DESERT/NON-INFLAMED IMMUNE CHECKPOINT MYELOID IMMUNE RESISTANCE PLATFORM PLATFORM PLATFORM Advanced pipeline with 3 Early-stage pipeline with Technology in development program

  12. Slide 12: Compugen's Immuno-Oncology Pipeline

    COMPUGEN’S IMMUNO-ONCOLOGY PIPELINE From Code to Cure® PROGRAM PARTNER DISEASE STAGE OF DEVELOPMENT Expansion to Lung, COM701 Breast, Ovarian PHASE 1 PVRIG inhibitor Endometrial, Colorectal COM701 + Opdivo® * PHASE 1 PVRIG + PD-1 inhibitors COM701 + Opdivo® + BMS-986207 Expansion to Ovarian, PHASE 1

  13. Slide 13: Innovative Cancer Immunotherapy Portfolio

    INNOVATIVE CANCER IMMUNOTHERAPY PORTFOLIO: TO OVERCOME RESISTANCE TO IMMUNOTHERAPY www.cgen.com I

  14. Slide 14: PVRIG: A Novel Checkpoint Target in the TIGIT/DNAM Axis

    PVRIG: A NOVEL CHECKPOINT TARGET IN THE TIGIT/DNAM AXIS TUMOR CELL / • PVRIG – internally discovered by APC Compugen’s discovery platform • DNAM axis – two parallel and PVRL2 PVR complementary inhibitory pathways (PVRIG & TIGIT) DNAM • PVRL2 broadly expressed in PVRIG PD-L1 positive and negative tum

  15. Slide 15: PVRIG Pathway in the DNAM Axis

    PVRIG PATHWAY IN THE DNAM AXIS Potential Intersection Between PVRIG/TIGIT and PD-1 Pathways Support Combination Approach to Overcome Immunotherapy Resistance Biomarker and Biology-Driven Drug Combination Approach www.cgen.com I 15 15

  16. Slide 16: COM701: First-in-Class Anti-PVRIG Antibody

    COM701: A FIRST-IN-CLASS ANTI-PVRIG THERAPEUTIC MONOCLONAL ANTIBODY Ongoing Phase 1 study in patients with advanced solid Combination therapy strategy based on deep tumors who have exhausted standard treatment options understanding of DNAM axis biology treatments • Signals of anti-tumor activity in

  17. Slide 17: Biomarker-Driven Approach Supports COM701

    BIOMARKER-DRIVEN APPROACH SUPPORTS COM701 MONOTHERAPY AND COMBINATION THERAPY TARGET INDICATIONS EXPRESS HIGHER PVRL2 RELATIVE TO PVR • PVRL2 highly expressed in many solid tumors • PVRL2 commonly expressed in both PD-L1 positive and negative tumors • PVRIG may serve as a dominant inhibitory checkpo

  18. Slide 18: COM701: Synergistic T Cell Activation with PD-1 or TIGIT Inhibitors

    COM701: SYNERGISTIC T CELL ACTIVATION WITH PD-1 OR TIGIT INHIBITORS COM701 +/- anti-TIGIT COM701 +/- anti-PD-1 Triple combination Whelan, et al., Cancer Immunol Res. 2019 www.cgen.com I 18 18

  19. Slide 19: PVRIG Knockout or Inhibition Reduces Tumor Growth in Mouse Models

    PVRIG KNOCKOUT OR INHIBITION REDUCES TUMOR GROWTH IN COMBINATION WITH PD-L1 OR TIGIT IN MOUSE MODELS PVRIG KO MICE (MC38) anti-PVRIG + anti-PD-L1 (CT26) PVRIG + TIGIT Double KO (B16) Control IgG Wild-type Mean Tumor Volume (mm3 ) 2500 WT a PD-L1 PVRIG -/- KO WT + αPD-L1 a PD-L1+ a-mPVRIG TIGIT -/- 2

  20. Slide 20: PVRIG and TIGIT: Complementary but Distinct Pathways

    PVRIG AND TIGIT – COMPLEMENTARY BUT DISTINCT PATHWAYS PVRIG preferentially TIGIT preferentially binds PVRL2 binds PVR Differentially expressed in Differentially expressed on Differentially expressed in tumor types immune cell types the tumor microenvironment PVRL2 expression is more TIGIT and PVRIG

  21. Slide 21: PVRL2 and PVR Exhibit Distinct Expression Patterns

    PVRL2 AND PVR ALSO EXHIBIT DISTINCT EXPRESSION PATTERNS PVRL2 expression is more dominant compared to PVR in certain cancers, such as breast, endometrial, and ovarian More dominant expression of PVRL2 on some tumor types T / NK Cells Dendritic Cells High PVRL2 expression Tumor Cells Myeloid Cells Hi

  22. Slide 22: PVRIG/PVRL2 Pathway Expressed on Key Immune Cell Populations

    PVRIG/PVRL2 PATHWAY EXPRESSED ON KEY IMMUNE CELL POPULATIONS INVOLVED IN T CELL PRIMING PVRIG expression on TSCM cells PVRL2 expression across various dendritic cell types PVRIG TIGIT PD-1 RNA Expression PVRL2 TSCM Exhausted TSCM Exhausted TSCM Exhausted NSCLC sample; single cell RNA analysis of Gau

  23. Slide 23: COM701 Clinical Programs

    COM701 CLINICAL PROGRAMS Phase 1 Arm A Phase 1/2 Monotherapy Monotherapy Triple Combination Dose Escalation Dose Escalation Cohort Expansion Escalating doses of COM701 with fixed doses of (20 patients; progressed on SOC) Opdivo® + BMS-986207 Study Objectives All-comers NSCLC, Ovarian, Breast, • Safe

  24. Slide 24: COM701: Signals of Anti-Tumor Activity

    COM701: SIGNALS OF ANTI-TUMOR ACTIVITY Monotherapy and Combination Dose Escalation Study (AACR Data Presentation, April 2020) • COM701 well-tolerated, no DLTs reported as monotherapy and in combination with Opdivo® Safety Profile • 16 patients in Arm A; 12 patients in Arm B • Two confirmed partial r

  25. Slide 25: Summary of Investigator-Assessed Response

    SUMMARY OF INVESTIGATOR-ASSESSED RESPONSE (per RECIST v1.1 DLT-EVALUABLE POPULATION) Data from Monotherapy and Combination Dose Escalation Study Arm A (N = 16) Arm B (N = 12) N (%) N (%) Overall Response rate (CR+PR) 1 (6) 1 (8) Disease control rate (CR+PR+SD) 11 (69) 9 (75) Durable stable disease (

  26. Slide 26: COM701 Monotherapy Dose Escalation – Arm A

    COM701 MONOTHERAPY DOSE ESCALATION – ARM A Data cut www.cgen.com I 26 26

  27. Slide 27: COM701 Dose Escalation + Fixed Dose Opdivo – Arm B

    COM701 DOSE ESCALATION + FIXED DOSE OPDIVO® – ARM B www.cgen.com I 27 27

  28. Slide 28: COM701: Encouraging Preliminary Clinical Data

    COM701: ENCOURAGING PRELIMINARY CLINICAL DATA Confirmed Partial Responses and Durable Stable Disease in Highly Refractory Patients Patients with durable Confirmed partial Maximum prior anti- 2 responses 6 responses of stable disease ≥ 6 months 15 cancer therapies Encouraging signals of anti-tumor ac

  29. Slide 29: COM902: Anti-TIGIT Therapeutic Monoclonal Antibody

    COM902: ANTI-TIGIT THERAPEUTIC MONOCLONAL ANTIBODY Potential to Fully Address DNAM Axis in Combination with COM701 Potential Best- High affinity – femtomolar – anti-TIGIT monoclonal antibody in-Class In vitro activity comparable or superior to TIGIT antibodies in clinical development Data-driven Pre

  30. Slide 30: COM902: A High Affinity Anti-TIGIT Antibody

    COM902: A HIGH AFFINITY ANTI-TIGIT ANTIBODY High affinity TIGIT binding Superior binding compared Enhances tumor infiltrating (650 fM) to clinical TIGIT benchmarks T-cells activation ex-vivo 4500 4000 3500 3000 gMFI 2500 2000 1500 1000 0.001 0.01 0.1 1 10 100 1000 [mAb] (Binding Site, nM) SITC, Nove

  31. Slide 31: COM902 Phase 1 Study

    COM902 PHASE 1 STUDY Identifier: NCT04354246 Monotherapy Dose Escalation Study Objectives All-comers, advanced malignancies who exhausted available treatment options • Safety & tolerability • PK/PD Administered IV every 3 weeks • Clinical activity Up to 7 dose escalation cohorts may be evaluated unt

  32. Slide 32: Strategic Collaborations: External Validation of Internally Discovered Targets

    STRATEGIC COLLABORATIONS: EXTERNAL VALIDATION OF INTERNALLY DISCOVERED TARGETS www.cgen.com I

  33. Slide 33: Partnerships with Leading Pharma Companies

    PARTNERSHIPS WITH LEADING PHARMA COMPANIES Clinical Trial Collaboration Development and License Agreement and Equity Investment Commercialization Agreement March 2018 October 2018, Amended February 2020 August 2013 $12M strategic equity investment Over $30M in upfront and milestone $10M upfront paym

  34. Slide 34: Financial Position

    FINANCIAL POSITION CASH • ~$133 million as of September 30, 2020 BALANCE • No Debt GROSS CASH EXPENDITURES • 2020 expected gross cash expenditures ~$27 million (excludes any cash inflows) • ~$1.2 billion (October 2020) MARKET • NASDAQ (CGEN); Nasdaq Biotechnology Index CAPITALIZATION • TASE (CGEN.TA

  35. Slide 35: Strong Execution and Near-Term Value Drivers

    STRONG EXECUTION AND NEAR-TERM VALUE DRIVERS COM701 COM902 • Presented encouraging data from monotherapy and combination • Initiated Phase 1 dose escalation study all comers with Opdivo® dose escalation studies at AACR in patients with advanced solid malignancies in • Completed enrollment in combina

  36. Slide 36: Corporate Overview

    CORPORATE OVERVIEW November 2020

Compugen — Investor Presentation (November 2020) on 6ix